Literature DB >> 24829355

Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness.

Rami Sommerstein1, Joel Ramos da Palma2, Stephan Olschläger3, Andreas Bergthaler1, Leticia Barba3, Boris P-L Lee1, Antonella Pasquato2, Lukas Flatz4.   

Abstract

UNLABELLED: A key characteristic of arenaviruses is their ability to establish persistent infection in their natural host. Different factors like host age, viral dose strain, and route of infection may contribute to the establishment of persistence. However, the molecular mechanisms governing persistence are not fully understood. Here, we describe gain-of-function mutations of lymphocytic choriomeningitis virus (LCMV) expressing Lassa virus (LASV) GP, which can prolong viremia in mice depending on the sequences in the GP-2 cytoplasmic tail. The initial mutant variant (rLCMV/LASV mut GP) carried a point mutation in the cytosolic tail of the LASV glycoprotein GP corresponding to a K461G substitution. Unlike what occurred with the original rLCMV/LASV wild-type (wt) GP, infection of C57BL/6 mice with the mutated recombinant virus led to a detectable viremia of 2 weeks' duration. Further replacement of the entire sequence of the cytosolic tail from LASV to LCMV GP resulted in increased viral titers and delayed clearance of the viruses. Biosynthesis and cell surface localization of LASV wt and mut GPs were comparable. IMPORTANCE: Starting from an emerging virus in a wild-type mouse, we engineered a panel of chimeric Lassa/lymphocytic choriomeningitis viruses. Mutants carrying a viral envelope with the cytosolic tail from the closely related mouse-adapted LCMV were able to achieve a productive viral infection lasting up to 27 days in wild-type mice. Biochemical assays showed a comparable biosynthesis and cell surface localization of LASV wt and mut GPs. These recombinant chimeric viruses could allow the study of immune responses and antivirals targeting the LASV GP.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24829355      PMCID: PMC4135970          DOI: 10.1128/JVI.00236-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P.

Authors:  O Lenz; J ter Meulen; H D Klenk; N G Seidah; W Garten
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

2.  X-ray structure of the arenavirus glycoprotein GP2 in its postfusion hairpin conformation.

Authors:  Sébastien Igonet; Marie-Christine Vaney; Clemens Vonrhein; Clemens Vonhrein; Gérard Bricogne; Enrico A Stura; Hans Hengartner; Bruno Eschli; Félix A Rey
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

Review 3.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

4.  Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression.

Authors:  Andreas Bergthaler; Lukas Flatz; Ahmed N Hegazy; Susan Johnson; Edit Horvath; Max Löhning; Daniel D Pinschewer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

5.  The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain.

Authors:  César G Albariño; Brian H Bird; Ayan K Chakrabarti; Kimberly A Dodd; Mike Flint; Eric Bergeron; David M White; Stuart T Nichol
Journal:  J Virol       Date:  2011-07-27       Impact factor: 5.103

6.  Genetic diversity among Lassa virus strains.

Authors:  M D Bowen; P E Rollin; T G Ksiazek; H L Hustad; D G Bausch; A H Demby; M D Bajani; C J Peters; S T Nichol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  The role of proteolytic processing and the stable signal peptide in expression of the Old World arenavirus envelope glycoprotein ectodomain.

Authors:  Dominique J Burri; Antonella Pasquato; Joel Ramos da Palma; Sebastien Igonet; Michael B A Oldstone; Stefan Kunz
Journal:  Virology       Date:  2012-12-04       Impact factor: 3.616

8.  Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus.

Authors:  Andrew M Lee; Justin Cruite; Megan J Welch; Brian Sullivan; Michael B A Oldstone
Journal:  Virology       Date:  2013-05-16       Impact factor: 3.616

9.  Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells.

Authors:  N Sevilla; S Kunz; A Holz; H Lewicki; D Homann; H Yamada; K P Campbell; J C de La Torre; M B Oldstone
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

Review 10.  Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.

Authors:  Stephan Olschläger; Lukas Flatz
Journal:  PLoS Pathog       Date:  2013-04-11       Impact factor: 6.823

View more
  9 in total

1.  Biological Characterization of Conserved Residues within the Cytoplasmic Tail of the Pichinde Arenaviral Glycoprotein Subunit 2 (GP2).

Authors:  Hinh Ly; Yuying Liang; Junjie Shao; Qinfeng Huang; Xiaoying Liu; Da Di; Mythili Dileepan; Morgan Brisse
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

2.  Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.

Authors:  Masaharu Iwasaki; Cherie T Ng; Beatrice Cubitt; Juan C de la Torre
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

3.  Axl Can Serve as Entry Factor for Lassa Virus Depending on the Functional Glycosylation of Dystroglycan.

Authors:  Chiara Fedeli; Giulia Torriani; Clara Galan-Navarro; Marie-Laurence Moraz; Hector Moreno; Gisa Gerold; Stefan Kunz
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

4.  Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria.

Authors:  Maryam Ibrahim Buba; Mahmood Muazu Dalhat; Patrick Mboya Nguku; Ndadilnasiya Waziri; Jibreel Omar Mohammad; Idriss Mohammed Bomoi; Amaka Pamela Onyiah; Jude Onwujei; Muhammad Shakir Balogun; Adebobola Toluwalashe Bashorun; Peter Nsubuga; Abdulsalami Nasidi
Journal:  Am J Public Health       Date:  2017-12-21       Impact factor: 9.308

5.  Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis.

Authors:  Joel Oppliger; Giulia Torriani; Antonio Herrador; Stefan Kunz
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

6.  Dynamic Dystroglycan Complexes Mediate Cell Entry of Lassa Virus.

Authors:  Antonio Herrador; Chiara Fedeli; Emilia Radulovic; Kevin P Campbell; Hector Moreno; Gisa Gerold; Stefan Kunz
Journal:  mBio       Date:  2019-03-26       Impact factor: 7.867

Review 7.  Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors.

Authors:  Morgan E Brisse; Hinh Ly
Journal:  Front Immunol       Date:  2019-03-13       Impact factor: 7.561

8.  Human LAMP1 accelerates Lassa virus fusion and potently promotes fusion pore dilation upon forcing viral fusion with non-endosomal membrane.

Authors:  You Zhang; Juan Carlos de la Torre; Gregory B Melikyan
Journal:  PLoS Pathog       Date:  2022-08-15       Impact factor: 7.464

9.  The Role of Receptor Tyrosine Kinases in Lassa Virus Cell Entry.

Authors:  Chiara Fedeli; Hector Moreno; Stefan Kunz
Journal:  Viruses       Date:  2020-08-06       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.